Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short term Debt (2017 - 2025)

Historic Short term Debt for Ani Pharmaceuticals (ANIP) over the last 11 years, with Q3 2025 value amounting to $15.2 million.

  • Ani Pharmaceuticals' Short term Debt rose 11310.12% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year increase of 11310.12%. This contributed to the annual value of $9.2 million for FY2024, which is 2522.42% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Short term Debt stood at $15.2 million, which was up 11310.12% from $13.2 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Short term Debt high stood at $25.0 million for Q2 2023, and its period low was $850000.0 during Q4 2021.
  • Moreover, its 5-year median value for Short term Debt was $11.2 million (2025), whereas its average is $10.1 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Short term Debt soared by 284411.76% in 2023 and then tumbled by 9660.34% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Short term Debt (Quarter) stood at $850000.0 in 2021, then changed by 0.0% to $850000.0 in 2022, then surged by 1343.06% to $12.3 million in 2023, then dropped by 25.22% to $9.2 million in 2024, then soared by 66.17% to $15.2 million in 2025.
  • Its Short term Debt was $15.2 million in Q3 2025, compared to $13.2 million in Q2 2025 and $11.2 million in Q1 2025.